Latest Biotech Sector News

Starpharma reports steady progress in its DEP® drug development programs, launches new marketing campaigns in key regions, and maintains a strong cash position of $17.2 million as it refines clinical strategies and partnerships.

Avecho Biotechnology has responded to an ASX price query, confirming no undisclosed information exists to explain recent trading spikes, while highlighting market speculation linked to its Phase III CBD insomnia trial.

Arovella Therapeutics has requested a voluntary suspension of its ASX-listed securities pending a material announcement on a capital raising, expected by 17 February 2025.

Biotron Limited reported a robust net cash inflow of $1.095 million for the December 2024 quarter, driven largely by government grants, supporting its operational stability despite ongoing R&D expenses.

BluGlass Limited has unveiled significant advances in gallium nitride (GaN) laser technology at SPIE Photonics West, filing three US provisional patents and demonstrating a powerful integrated laser amplifier. These developments position the company at the forefront of quantum, aerospace, and biotech photonics innovation.